Connect your AI

Citius Oncology, Inc. CTOR Revenue

Revenue at other companies

BeldenBDC

$696.38M+11.4%

Rumble, Inc.RUM

$25.46M+7.4%

Richtech Robotics Inc.RR

$1.15M-8.8%

ePlusPLUS

$581.63M+21.7%

Solidion Technology, Inc.STI

$85.43K—

NXT

Next Technology HoldingNXTT

$465.23K—

Other financials

Income statement

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

Operating cash flow-$3.8M-179%

Valuation

Market cap$60.45M-74.7%

Returns & leverage

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Citius Oncology, Inc.'s revenue?: Citius Oncology, Inc. (CTOR) reported revenue of $1.67M in Q1 2026.